MLLCF (Molecular Partners AG) Accounts Payable & Accrued Expense: $10.77 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MLLCF Molecular Partners AG MLLCF
34 GF Score
Price $3.80
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Molecular Partners AG Accounts Payable & Accrued Expense?

Molecular Partners AG MLLCF 34 Accounts Payable & Accrued Expense is $10.77 Mil as of Jun. 2026. GuruFocus rates MLLCF with a GF Score™ of 34/100 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Molecular Partners AG's quarterly accounts payable & accrued expense declined from Dec. 2025 ($12.32 Mil) to Mar. 2026 ($9.64 Mil) but then increased from Mar. 2026 ($9.64 Mil) to Jun. 2026 ($10.77 Mil).

Molecular Partners AG's annual accounts payable & accrued expense increased from Dec. 2023 ($10.26 Mil) to Dec. 2024 ($10.73 Mil) and increased from Dec. 2024 ($10.73 Mil) to Dec. 2025 ($12.32 Mil).

Molecular Partners AG Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for Molecular Partners AG's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecular Partners AG Accounts Payable & Accrued Expense Chart

Molecular Partners AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.85 10.35 10.26 10.73 12.32

Molecular Partners AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.36 13.21 12.32 9.64 10.77
MLLCF
34GF Score
Molecular Partners AG MLLCF
Accounts Payable & Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Molecular Partners AG Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of $10.77 Mil mean?
Molecular Partners AG (MLLCF) has a Accounts Payable & Accrued Expense of $10.77 Mil as of Jun. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Molecular Partners AG and its competitors.
Is Molecular Partners AG's Accounts Payable & Accrued Expense too high?
Molecular Partners AG's current Accounts Payable & Accrued Expense is $10.77 Mil. Overall, Molecular Partners AG has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Accounts Payable & Accrued Expense compare to VRTX and REGN?
Molecular Partners AG's Accounts Payable & Accrued Expense of $10.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Biotechnology company?
A good Accounts Payable & Accrued Expense depends on the Biotechnology industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Molecular Partners AG and its competitors. Molecular Partners AG's current Accounts Payable & Accrued Expense is $10.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The current Accounts Payable & Accrued Expense is $10.77 Mil. Molecular Partners AG's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Accounts Payable & Accrued Expense is $10.77 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Molecular Partners AG Business Description

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
34GF Score

Get the complete analysis for MLLCF

Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.80
Price